Literature DB >> 8549419

Activity of quinolones against mycobacteria.

M R Jacobs1.   

Abstract

The fluoroquinolones have been shown to be highly active in vitro against many mycobacterial species, including most strains of Mycobacterium tuberculosis and M. fortuitum, and some strains of M. kansasii, M. avium-intracellulare (MAI) complex and M. leprae. Ciprofloxacin, ofloxacin and sparfloxacin are the best studied of this class of drugs to date, and they are among the most active of these against M. tuberculosis and other mycobacteria. The use of ofloxacin in the treatment of patients with multidrug-resistant pulmonary tuberculosis has resulted in the selection of quinolone-resistant mutants in a few patients. Many strains of MAI, however, are resistant to fluoroquinolones, and structure-activity relationship studies have been undertaken to identify the moieties associated with activity and inactivity. The most important features determining activity against MAI were found to be a cyclopropyl ring at the N1 position, fluorine atoms at positions C6 and C8, and a C7 heterocyclic substituent. On the basis of these structural requirements, a series of compounds were tested, and many did indeed show good activity against MAI in vitro. Application of these data to macrophage and animal models is in progress. Clinical evaluation of some of these new fluoroquinolones is also being undertaken in multidrug-resistant tuberculosis and MAI and M. leprae infections. Although the development of resistance and the influence of host factors may limit their use, they have considerable potential if prudently used.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8549419     DOI: 10.2165/00003495-199500492-00011

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  25 in total

Review 1.  Mycobacteria and the new quinolones.

Authors:  D C Leysen; A Haemers; S R Pattyn
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

2.  MICs and MBCs of Win 57273 against Mycobacterium avium and M. tuberculosis.

Authors:  L B Heifets; P J Lindholm-Levy
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

Review 3.  Treatment of multidrug-resistant tuberculosis.

Authors:  M D Iseman
Journal:  N Engl J Med       Date:  1993-09-09       Impact factor: 91.245

4.  Anti-Mycobacterium avium activity of quinolones: in vitro activities.

Authors:  G Klopman; S Wang; M R Jacobs; S Bajaksouzian; K Edmonds; J J Ellner
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

5.  New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.

Authors:  J M Domagala; L D Hanna; C L Heifetz; M P Hutt; T F Mich; J P Sanchez; M Solomon
Journal:  J Med Chem       Date:  1986-03       Impact factor: 7.446

6.  Inhibition of Micrococcus luteus DNA gyrase by norfloxacin and 10 other quinolone carboxylic acids.

Authors:  M M Zweerink; A Edison
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191

7.  In vitro activities of norfloxacin and ciprofloxacin against Mycobacterium tuberculosis, M. avium complex, M. chelonei, M. fortuitum, and M. kansasii.

Authors:  J D Gay; D R DeYoung; G D Roberts
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

8.  Activities of sparfloxacin, azithromycin, temafloxacin, and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages.

Authors:  C Perronne; A Gikas; C Truffot-Pernot; J Grosset; J L Vilde; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

9.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

10.  In vitro susceptibilities of rapidly growing mycobacteria to newer antimicrobial agents.

Authors:  N Khardori; H Nguyen; B Rosenbaum; K Rolston; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1994-01       Impact factor: 5.191

View more
  7 in total

Review 1.  The appropriate use of quinolones.

Authors:  A Percival
Journal:  Drugs       Date:  1996       Impact factor: 9.546

2.  In vitro susceptibility of mycoplasmas to a new quinolone, BAY Y 3118.

Authors:  H Renaudin; C Bébéar
Journal:  Drugs       Date:  1995       Impact factor: 9.546

3.  In vitro activities of six fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first-line antituberculosis drugs.

Authors:  M J Ruiz-Serrano; L Alcalá; L Martínez; M Díaz; M Marín; M J González-Abad; E Bouza
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

4.  Antimycobacterial activities of novel levofloxacin analogues.

Authors:  K Kawakami; K Namba; M Tanaka; N Matsuhashi; K Sato; M Takemura
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

5.  Clinical effects of gemifloxacin on the delay of tuberculosis treatment.

Authors:  Seo Yun Kim; Jae-Joon Yim; Jong Sun Park; Sung Soo Park; Eun Young Heo; Chang-Hoon Lee; Hee Soon Chung; Deog Kyeom Kim
Journal:  J Korean Med Sci       Date:  2013-03-04       Impact factor: 2.153

Review 6.  Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability.

Authors:  R Davis; A Markham; J A Balfour
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

7.  Prioritizing genomic drug targets in pathogens: application to Mycobacterium tuberculosis.

Authors:  Samiul Hasan; Sabine Daugelat; P S Srinivasa Rao; Mark Schreiber
Journal:  PLoS Comput Biol       Date:  2006-06-09       Impact factor: 4.475

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.